Trial reportJournal of back and musculoskeletal rehabilitation2026
Extracorporeal magnetotransduction therapy (EMTT) for management of musculoskeletal disorders: A double-blind, placebo-controlled, randomised trial.
Trial report in Journal of back and musculoskeletal rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/ObjectivesMusculoskeletal pain limits function and quality of life worldwide. This study investigated whether Extracorporeal Magnetotransduction Therapy (EMTT) improves pain and physical function in patients with degenerative joint diseases and enthesopathies.MethodsIn this single-center, randomized, double-blind, placebo-controlled trial, 126 patients with >6 weeks of pain from knee osteoarthritis, rotator cuff enthesopathy, or lumbar spondyloarthrosis were randomized to EMTT (80 mT, 8 Hz, 10,000 pulses/session) or sham therapy once weekly for eight weeks. The primary outcome was quality of life measured by the SF-12 Physical (PCS) and Mental (MCS) Composite Scales. Secondary outcome was pain on the Visual Analog Scale (VAS). Differences were analyzed using the Wilcoxon-Mann-Whitney test and Mann-Whitney estimator.ResultsBaseline PCS, MCS, and VAS were comparable between groups. At six weeks, EMTT led to significantly higher PCS (42.9 vs. 38.6, p < 0.001) and lower VAS pain (2.8 vs. 4.3, p < 0.001), with effects persisting at 12 weeks (PCS 45.5 vs. 38.7; VAS 2.2 vs. 4.2; all p < 0.001). MCS showed no significant differences. Mild discomfort and skin redness occurred more often with EMTT.ConclusionsEMTT appears effective in improving physical function and reducing pain in degenerative musculoskeletal conditions, with minor side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.